Sun Pharma Leads Pharma Stocks Decline After Trump Hikes Tariff To 100%
Sun Pharmaceutical Industries Ltd. declined nearly 5% on Friday as Trump announced 100% tariff on the Pharmaceutical sector unless the company has manufacturing capacity in the United States.
Other Pharmaceutical stocks seeing decline are Cipla Ltd., Dr Reddys Laboratories Ltd., Lupin Ltd. and Biocon Ltd., however the impact on these companies is largely contained since the US tariffs mainly target branded and patented drugs, where multinational companies like Pfizer Inc. and Novo Nordisk Inc. dominate.
It is yet unclear whether complex generics and specialty drugs from India could also face scrutiny. Sun Pharmaceutical Industries and Biocon are key branded players in the US.
Sun Pharma may have some impact until it announces its US capex plans. It exports specialty drugs like ILUMYA, CEQUA, WINLEVI and ODOMZO. This category contributes 19% to overall revenue.
In FY25, Global Specialty sales rose by 17.1%, reaching $1,216 million. A significant contributor to this growth was ILUMYA, which saw a 17% increase in global sales, totaling $681 million for the year. Additionally, Specialty R&D accounted for 36% of the company's total R&D spend in Q4FY25.
The scrip rose as much as 4.88% to Rs 1,548 apiece. It pared gains to trade 2.94% lower at Rs 1,579.60 apiece, as of 09:37 a.m. This compares to a 0.50% decline in the NSE Nifty 50 Index.
It has fallen 16.79% in the last 12 months. Total traded volume so far in the day stood at 1 times its 30-day average. The relative strength index was at 39.
Out of 44 analysts tracking the company, 35 maintain a 'buy' rating, four recommend a 'hold,' and five suggest 'sell,' according to Bloomberg data. The average 12-month consensus price target implies an upside of 22.1%
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
